/publications/issue/2009/2009-05/GenericProductNews-0509

Generic Product News

Author:

Risperidone Oral Solution
Marketed by:

Teva Pharmaceuticals (North Wales, PA)
Compared to:
Risperdal Oral Solution (Janssen, Division of Ortho-McNeil-Janssen Pharmaceuticals Inc)
Indication:
Teva Pharmaceuticals announced the introduction and availability of Risperidone Oral Solution. The product is AA-rated and bioequivalent to Risperdal Oral Solution. An atypical antipsychotic agent, Risperidone is indicated for treatment of schizophrenia in adults. It also can be used alone, or in combination with lithium or valproate, for the short-term treatment of acute manic or mixed episodes associated with bipolar 1 disorder in adults.
Dosage Form:
Oral solution: 1 mg/mL
For More Information:
www.tevausa.com
888-TEVA USA (888-838-2872)

Dorzolamide Ophthalmic Solution and Dorzolamide/Timolol Sterile Ophthalmic Solution
Marketed by:
Sandoz Inc (Princeton, NJ)
Compared to:
Trusopt: Dorzolamide Ophthalmic Solution; Cosopt: Dorzolamide/ Timolol Sterile Ophthalmic Solution (Merck&Co Inc)
Indication:
Sandoz announced the introduction of Dorzolamide Ophthalmic Solution and Dorzolamide/Timolol Sterile Ophthalmic Solution in the United States. Dorzolamide is a carbonic anhydrase inhibitor and Dorzolamide/Timolol is a combination of dorzolamide and timolol, a beta-blocker agent. Both treatments are indicated for ocular hypertension and open-angle glaucoma.
Dosage Form:
Dorzolamide: 20 mg/mL; Dorzolamide/Timolol: 20 mg/mL of dorzolamide and 5 mg/mL of timolol
For More Information:
www.us.sandoz.com

Liothyronine Sodium
Marketed by:
Paddock Laboratories Inc (Minneapolis, MN)
Compared to:
Cytomel (King Pharmaceuticals)
Indication:
Paddock Laboratories has announced the availability of Liothyronine Sodium tablets. A thyroid hormone drug, Liothyronine Sodium is AB-rated to Cytomel. It is indicated for replacement or supplemental therapy in patients with hypothyroidism of any etiology except transient hypothyroidism during the recovery phase of subacute thyroiditis; as pituitary thyroid-stimulating hormone suppressants in the treatment or prevention of various types of euthyroid goiters, including thyroid nodules, subacute or chronic lymphocytic thyroiditis (Hashimoto’s), and multinodular goiter; and as diagnostic agents in suppression tests to differentiate suspected mild hyperthyroidism or thyroid gland autonomy.
Dosage Form:
5, 25, and 50 mcg
For More Information:
www.paddocklabs.com

Prednisolone Sodium Phosphate Oral Solution
Marketed by:
Amneal Pharmaceuticals (Hauppauge, NY)
Compared to:
Orapred (Sciele Pharma)
Indication:
The FDA has approved the abbreviated new drug application for Prednisolone Sodium Phosphate, USP Oral Solution in 15 mg/5 mL strength. The product is an AA-rated, therapeutically equivalent alternative to Orapred. The grape-flavored solution will be sold in both 237- and 437-mL sizes, making it the only 16-oz prednisolone solution available on the market. Prednisolone sodium phosphate does not require refrigeration.
Dosage Form:
15 mg/5 mL
For More Information:
www.amneal.com